Trimestre sensacional:
Q3 Highlights
Worldwide da Vinci procedures grew approximately 15% compared with the third quarter of 2016, driven primarily by growth in U.S. general surgery procedures and worldwide urologic procedures.
The Company shipped 169 da Vinci Surgical Systems compared with 134 in the third quarter of 2016.
The Company’s stockholders approved a three-for-one split of the Companys issued and outstanding common stock, which began trading on a split-adjusted basis on October 6, 2017.
Third quarter 2017 revenue of $806 million grew approximately 18% compared with $683 million for the third quarter of 2016. Third quarter 2017 revenue included $21 million that had previously been deferred in connection with a customer trade-out program that the Company had offered certain first quarter 2017 customers.
Third quarter 2017 GAAP net income was $298 million, or $2.55 per diluted share, compared with $211 million, or $1.77 per diluted share, for the third quarter of 2016.
Third quarter 2017 non-GAAP* net income was $324 million, or $2.77 per diluted share, compared with $246 million, or $2.06 per diluted share, for the third quarter of 2016. GAAP and non-GAAP* net income per diluted share for the third quarter of 2017 and 2016 included $0.59 and $0.13, respectively, of benefits from certain income tax items.
#1 de 1
